Table 1.
Clinical characteristics of the HyperPATH cohort by disease status
| Baseline characteristics | T2DM-HTN | T2DM-NTN | HTN | NTN |
|---|---|---|---|---|
| n | 51 | 30 | 451 | 209 |
| Age (yr) | 52.1 ± 8.3 | 49.4 ± 9.2 | 48.5 ± 8.9 | 39.2 ± 12.2 |
| Female gender (%) | 16 (27) | 13 (45) | 189 (42) | 105 (50) |
| Race (%) | ||||
| Caucasian | 34 (67) | 17 (59) | 381 (85) | 171 (82) |
| African-American | 15 (29) | 8 (28) | 54 (12) | 30 (14) |
| Other | 2 (4) | 4 (14) | 16 (3) | 6 (3) |
| BMI (kg/m2) | 30.2 ± 4.5 | 28.9 ± 4.5 | 28.1 ± 3.9 | 25.2 ± 3.6 |
| Fasting blood sugar (mg/dl) | 119 ± 48 | 109.5 ± 41 | 89 ± 13 | 86 ± 14 |
| Blood pressure (mm Hg) | ||||
| Systolic | 149.6 ± 20.6 | 122.4 ± 16.9 | 148.7 ± 19.4 | 111.0 ± 11.9 |
| Diastolic | 92.8 ± 19.3 | 75.0 ± 9.3 | 91.6 ± 15.5 | 67.2 ± 8.7 |
| MAP | 111.7 ± 17.2 | 90.8 ± 10.8 | 109.5 ± 13.6 | 81.3 ± 8.8 |
| eGFR (MDRD) | 87.6 ± 23 | 100.6 ± 19.5 | 93.2 ± 26.0 | 104.0 ± 26.4 |
| Urinary sodium HS | 236.6 ± 71.9 | 228.7 ± 68.7 | 231.1 ± 63.8 | 241.2 ± 70.6 |
| Urinary sodium LS | 14.4 ± 7.3 | 15.9 ± 8.4 | 13.4 ± 8.0 | 9.8 ± 7.5 |
| Total cholesterol (mg/dl) | 210.0 ± 44.9 | 174.6 ± 43.7 | 197.0 ± 39.5 | 164.5 ± 37.2 |
| LDL cholesterol (mg/dl) | 107.7 ± 31.6 | 98.5 ± 22.4 | 120.9 ± 34.3 | 95.8 ± 30.2 |
| HDL cholesterol (mg/dl) | 39.5 ± 11.7 | 49.6 ± 25.8 | 42.1 ± 13.4 | 50.2 ± 30.2 |
| Triglycerides (mg/dl)** | 133 ± 105 | 97 ± 137.5 | 125.0 ± 84 | 89 ± 63 |
| Medications (%) | ||||
| Sulfonyurea use | 7 (14) | 7 (23) | ||
| Metformin use | 7 (14) | 6 (20) | ||
| Insulin use | 3 (5) | 2 (6) | ||
| Statin use | 3 (5) | 6 (20) |
Results are shown as mean ± sd for normally distributed continuous variables, median ± interquartile range for nonnormal continuous variables (fasting glucose and triglycerides), and percentages for categorical variables. HDL, High-density lipoprotein; LDL, low-density lipoprotein; MDRD, modification of diet in renal disease formula.
**
Data represent median ± interquartile range.